XLO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Xilio Therapeutics Inc (XLO) is not a strong buy at the moment for a beginner investor with a long-term focus. Despite a significant YoY revenue increase in the latest quarter, the company remains unprofitable, with EPS declining and a negative net income. The technical indicators and trading trends do not suggest a clear upward momentum, and there are no strong catalysts or proprietary trading signals to justify immediate action. Holding off for now is recommended.
The MACD is positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 64.588, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 0.555, with resistance at 0.594 and support at 0.516, suggesting limited upside potential in the short term.
The company has secured $40 million in funding through a pre-funded warrant offering, with strong participation from institutional investors. Revenue increased significantly by 742.51% YoY in the latest quarter.
The company remains unprofitable, with a net income of -$16.29 million and a 50% YoY decline in EPS. The bearish moving averages and lack of significant insider or hedge fund activity further weigh on the stock.
In Q3 2025, revenue increased by 742.51% YoY to $19.07 million, and net income improved by 16.17% YoY to -$16.29 million. However, EPS dropped by 50% YoY to -0.11, indicating ongoing challenges in achieving profitability. Gross margin remained stable at 100%.
No recent analyst rating or price target changes are available.
